16217-15-5

Basic information

• Product Name: （s）-L-benzyl 2-methyl 4-oxopyrrolidine-1，2-dicarboxyl
• Synonyms: （s）-L-benzyl 2-methyl 4-oxopyrrolidine-1，2-dicarboxyl;（s）-L-benzyl-2-methyl 4-oxopyrrolidine-1，2-dicarboxylate;(2S)-4-Oxo-1,2-pyrrolidinedicarboxylic Acid 1-Benzyl 2-Methyl Ester;1-benzyloxycarbonyl-4-keto-(S)-proline Methyl ester;(S)-1-Benzyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate;1-benzyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate;(2S)-4-oxo-1,2-Pyrrolidinedicarboxylic acid 2-methyl 1-(phenylmethyl) ester;(S)-1-Benzyloxycarbonyl-4-oxoproline methyl ester
• CAS NO: 16217-15-5
• Molecular Formula: C₁₄H₁₅NO₅
• Molecular Weight: 277.275
• Mol File: 16217-15-5.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 422.051 °C at 760 mmHg
• Flash Point: 209.049 °C
• Appearance: /
• Density: 1.307g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.559
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform, Dichloromethane, Dimethylsulfoxide, Ethyl Acetate
• PKA: -3.91±0.40(Predicted)
• CAS DataBase Reference: （s）-L-benzyl 2-methyl 4-oxopyrrolidine-1，2-dicarboxyl(CAS DataBase Reference)
• NIST Chemistry Reference: （s）-L-benzyl 2-methyl 4-oxopyrrolidine-1，2-dicarboxyl(16217-15-5)
• EPA Substance Registry System: （s）-L-benzyl 2-methyl 4-oxopyrrolidine-1，2-dicarboxyl(16217-15-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 16217-15-5(Hazardous Substances Data)

Usage

Description

(S)-L-Benzyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxyl, also known as (S)-1-Benzyl 2-Methyl 4-Oxopyrrolidine-1,2-Dicarboxylate, is a light yellow oil with significant applications in the pharmaceutical industry. It is a synthetic compound that serves as a key intermediate in the development of various therapeutic agents.

Uses

Used in Pharmaceutical Industry:
(S)-L-Benzyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxyl is used as a key intermediate for the preparation of dipeptidyl peptidase IV inhibitors. These inhibitors play a crucial role in managing type 2 diabetes by regulating blood glucose levels and are known for their potential in treating other related metabolic disorders.
Additionally, (S)-L-Benzyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxyl is used as a building block in the synthesis of (hydroxy)(carbamoyl)pyrimidinones. These compounds have demonstrated potent activity as HIV integrase inhibitors, which are vital in the development of antiretroviral drugs for the treatment of HIV/AIDS.

InChI:InChI=1/C14H15NO5/c1-19-13(17)12-7-11(16)8-15(12)14(18)20-9-10-5-3-2-4-6-10/h2-6,12H,7-9H2,1H3/t12-/m0/s1

Upstream product

• 13504-85-3 (2S,4R)-1-(benzyloxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid 
• 501-53-1 benzyl chloroformate 
• 57653-35-7 (2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 1-benzyl 2-methyl 
• 618-27-9 hydroxy L-proline 
• 64187-48-0 methyl (2S,4R)-1-benzyloxycarbonyl-4-hydroxypyrrolidine-2-carboxylate 
• 67-56-1 methanol 
• 64187-47-9 1-benzyloxycarbonyl-4-keto-L-proline 
• 186581-53-3 diazomethane 
• 92246-88-3 N-carbobenzyloxy-trans-4-hydroxy-L-proline methyl ester 
• 79-37-8 oxalyl dichloride 
• 67-68-5 dimethyl sulfoxide 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 
• 132431-08-4 4-Oxo-pyrrolidine-2-carboxylic acid methyl ester 

Downstream Products

• 117653-36-8 methyl (2S,4E)-1-(benzyloxycarbonyl)-4-(2-tert-butoxy-2-oxoethylidene)-2-pyrrolidinecarboxylate 
• 1256390-39-2 (S)-7-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-1,4-dioxa-7-aza-spiro[4.4]nonane-8-carboxylic acid 2-(4-bromo-phenyl)-2-oxo-ethyl ester 
• 1256390-26-7 methyl ((S)-1-((S)-8-(5-(4-bromophenyl)-1H-imidazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonan-7-yl)-3-methyl-1-oxobutan-2-yl)carbamate 
• 1399843-64-1 methyl ((S)-3-methyl-1-oxo-1-((S)-8-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonan-7-yl)butan-2-yl)carbamate 
• 443685-85-6 C₁₅H₂₁NO₅S 
• 443984-01-8 (2S)-1-benzyloxycarbonyl-2-cyanomethyl-4-methylpyrrolidine 
• 443984-00-7 (2S)-1-benzyloxycarbonyl-4-methylproline methyl ester 
• 443983-99-1 (2S)-1-Benzyloxycarbonyl-2-hydroxymethyl-4-methylpyrrolidine 
• 443685-77-6 (2S)-4-Methylproline Methyl Ester 
• 1418177-68-0 methyl (2S,4R)-1-benzyloxycarbonyl-4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-carboxylate 
• 1349667-16-8 C₂₈H₂₉NO₄ 
• 1349049-59-7 methyl (2S,4R)-1-(4,4-diphenylbut-3-en-1-yl)-4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-carboxylate 
• 1418178-12-7 methyl (2S,4R)-4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-carboxylate 
• 1418178-11-6 C₁₂H₁₅NO₄ 

Relevant articles and documents

Novel μ opioid antagonists derived from the μ opioid agonists endomorphin and [Dmt1]DALDA (H-Dmt-D-Arg-Phe-Lys-NH2)

Hybrid analogues of the μ opioid agonists endomorphin and [Dmt1]DALDA (H-Dmt-D-Arg-Phe-Lys-NH2, Dmt?=?2′,6′-dimethyltyrosine) containing cis-4-amino-Pro, trans-4-amino-Pro, cis-4-aminoethyl-Pro or cis-4-guanidinylethyl-Pro in the 2 p

Compound as apoptosis protein inhibitor, and application thereof

The present invention belongs to the field of medical chemistry, relates to a class of compounds of apoptosis protein inhibitors, and applications thereof, and particularly provides a compound represented by a formula I, or an isomer thereof, a pharmaceut

As hepatitis c inhibitor spiro compound and its use in medicine

The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.